Didn't find what you were looking for?

Get in touch with us. We'd love to hear from you! Visit us for frequently asked questions and more information. Contact us First name* Last name* Email* Phone Multi-line address Country/Region* Address* City* Zip / Postal code* What are you looking for?* Book a test Event enquiry Press or Media Enquiry Other Message* Submit Terms & Conditions | Privacy Policy We'd love to hear from you Whether it’s research, technology, or partnership opportunities, we’re here to explore what’s next—together. Write to us Click the below button to book an OncoDiscover test. Book a test Our Address Visit Us Here’s where you can reach us in person. We look forward to welcoming you. US office 11842, Churchill Way, Porter Ranch, CA 91326 India office #203/6, Powai Lake Heights, Rambaug, Powai, Mumbai – 400076, Maharashtra, India India Lab 208 & 411, B Wing, GO Square, Aundh-Hinjewadi Road, Wakad, Pune - 411057, Maharashtra, India FAQS Frequently asked questions Answers to commonly asked questions about Actorius and our offerings. What does Actorius Innovations & Research Pvt. Ltd. do? Actorius focuses on advancing precision oncology through innovative research, diagnostics, and technology platforms. Our work is centered on understanding cancer biology in depth and translating insights into actionable outcomes. Who can reach out to Actorius? Researchers, clinicians, healthcare partners, institutions, and potential collaborators are welcome to contact us. We also engage with industry partners and organizations interested in advancing cancer diagnostics and care. How long does it take to receive a response after submitting the contact form? We typically respond within 1–2 business days. Queries that require technical or scientific review may take slightly longer, and we appreciate your patience. Can I request collaborations or partnerships through the contact form? Yes. The contact form can be used to initiate discussions around research collaborations, partnerships, or technology integrations. Please include relevant details so we can route your request appropriately. Where can I find more information about your services or products? Detailed information about our platforms, research focus, and offerings is available throughout the website. If you have a specific question not addressed online, feel free to contact us directly. Know More

Explore our Privacy Policy. Learn how your data is protected and securely managed with our Privacy Policy. Privacy Policy Date Updated: 03 March 2026 Actorius Innovations and Research Pvt. Ltd. (“we,” “us,” or “our”) is committed to protecting your privacy. This Privacy Policy explains how we collect, use, disclose, and safeguard your personal information when you access or use our website at [https://www.actorius.in ] (“Site”), in accordance with applicable Indian data protection laws, including the Information Technology Act, 2000 and the rules made thereunder. 1. Information We Collect We collect the following categories of information through our Site: a. Personal Information Information that may identify you and is voluntarily provided by you, including but not limited to: Full Name Email Address Phone Number (optional) Organization or Company Name (optional) Professional details you choose to share Any other information you voluntarily submit via contact forms or inquiries b. Usage Data Information automatically collected when you interact with our Site, such as: IP address Browser type and version Operating system Pages visited and time spent on the Site Referring and exit URLs Device identifiers Approximate location data (where permitted and with consent) 2. How We Use Your Information We use the information we collect to: Operate, maintain, and improve our Site Personalize and enhance your browsing experience Understand user behavior and site performance Respond to inquiries and provide requested information Communicate updates, insights, or promotional material (only with your consent) Ensure site security and prevent misuse or fraudulent activity Comply with applicable legal and regulatory obligations Your personal information will only be used for purposes consistent with this Privacy Policy. 3. Sharing of Information We do not sell, rent, or trade your personal information. We may share information only in the following situations: With trusted service providers who assist us in operating our Site (e.g., hosting, analytics), subject to confidentiality obligations When required by law, regulation, court order, or governmental authority To protect the rights, safety, or property of Actorius Innovations & Research Pvt. Ltd., our users, or others In connection with investigations of potential violations of our terms or applicable laws 4. Cookies and Tracking Technologies We use cookies and similar technologies to: Remember user preferences Analyze traffic and site usage Improve performance and functionality Deliver relevant content (where consent is provided) You may manage or disable cookies through your browser settings. Please note that disabling cookies may affect certain features of the Site. 5. Data Security We implement reasonable administrative, technical, and physical safeguards to protect your personal information from unauthorized access, disclosure, or misuse. While we strive to protect your data, no method of transmission over the internet or electronic storage is completely secure, and absolute security cannot be guaranteed. 6. Your Rights Subject to applicable Indian laws, you may have the right to: Access the personal data we hold about you Request correction of inaccurate or incomplete data Request deletion of your personal data, subject to legal requirements Restrict or object to certain processing activities Withdraw consent where processing is based on consent To exercise these rights, please contact us using the details provided in Section 9. 7. Children’s Privacy The Site is not intended for use by individuals under the age of 18. We do not knowingly collect personal data from minors. If we become aware that a minor has provided personal information, we will take steps to delete such data promptly. 8. Changes to This Privacy Policy We may update this Privacy Policy from time to time to reflect changes in legal, regulatory, or operational requirements. Any updates will be posted on this page with a revised “Last Updated” date. We encourage you to review this policy periodically. 9. Contact Us If you have any questions, concerns, or requests regarding this Privacy Policy, please contact us at: Website: [https://www.actorius.in/contact] Email: [info@actorius.com ]

Explore our Actorius Innovation's Terms & Conditions. Understand your rights and obligations with our comprehensive Terms & Conditions. Terms & Conditions Date Updated: 03 March 2026 Welcome to the official website of Actorius Innovations & Research Pvt. Ltd., accessible at [https://actorius.in ] (the “Website”). By accessing or using this Website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing, browsing, or using this Website, you acknowledge that you have read, understood, and agreed to be bound by these Terms and Conditions, along with our Privacy Policy. If you do not agree with any part of these terms, you must discontinue use of the Website immediately. 2. Use of the Website The content on this Website is provided for general informational and educational purposes only and is subject to change without prior notice. You agree to use this Website solely for lawful purposes and in a manner that does not infringe the rights of, restrict, or inhibit the use of this Website by any third party. Any unauthorised use, misuse, or abuse of this Website may give rise to a claim for damages and/or be a criminal offence under applicable Indian laws. 3. Intellectual Property Rights All content on this Website, including but not limited to text, graphics, logos, icons, images, illustrations, videos, audio, software, design elements, and data compilations, is the property of Actorius Innovations & Research Pvt. Ltd. or its licensors and is protected by applicable Indian and international intellectual property laws. You may not copy, reproduce, modify, republish, upload, post, transmit, distribute, or exploit any content from this Website in any form or by any means without prior written permission from Actorius Innovations & Research Pvt. Ltd. 4. Third-Party Links This Website may contain links to third-party websites or resources provided for convenience or informational purposes only. Such links do not constitute an endorsement, sponsorship, or recommendation by Actorius Innovations & Research Pvt. Ltd. We have no control over the content, policies, or practices of third-party websites and accept no responsibility or liability for any loss or damage arising from your use of such websites. 5. Disclaimer of Warranties and Limitation of Liability This Website and its content are provided on an “as is” and “as available” basis. Actorius Innovations & Research Pvt. Ltd. makes no representations or warranties, express or implied, regarding the accuracy, completeness, reliability, suitability, or availability of the Website or its content. To the fullest extent permitted by law, Actorius Innovations & Research Pvt. Ltd. shall not be liable for any direct, indirect, incidental, special, consequential, or exemplary damages, including but not limited to loss of profits, data, goodwill, or other intangible losses, arising out of or in connection with your use of, or inability to use, the Website. Nothing in these Terms shall exclude or limit any liability that cannot be excluded under applicable Indian law. 6. Indemnification You agree to indemnify, defend, and hold harmless Actorius Innovations & Research Pvt. Ltd., its directors, officers, employees, affiliates, partners, agents, and licensors from and against any claims, liabilities, damages, losses, costs, or expenses (including reasonable legal fees) arising from: Your use or misuse of the Website Your violation of these Terms and Conditions Your infringement of any intellectual property or other rights of any third party 7. Governing Law and Jurisdiction These Terms and Conditions shall be governed by and construed in accordance with the laws of India. You agree that any disputes arising out of or relating to these Terms or the use of the Website shall be subject to the exclusive jurisdiction of the courts located in [ Pune, Maharashtra, India]. 8. Modifications to Terms Actorius Innovations & Research Pvt. Ltd. reserves the right to revise, modify, or update these Terms and Conditions at any time without prior notice. Any changes will be effective immediately upon posting on the Website. Your continued use of the Website after such changes constitutes acceptance of the revised Terms. 9. Services, Refunds, and Cancellations Where applicable, services offered by Actorius Innovations & Research Pvt. Ltd., including research, diagnostics, analytics, or related scientific and healthcare solutions, are subject to specific terms communicated at the time of engagement. Due to the specialized and scientific nature of our offerings, refunds or cancellations may be limited or not permitted once a service has commenced, data has been processed, or samples/materials have been analyzed. Any requests for cancellation or refund, where applicable, must be submitted in writing through our official communication channels and will be evaluated on a case-by-case basis. 10. Contact Information If you have any questions, concerns, or requests regarding these Terms and Conditions, please contact us at: Actorius Innovations & Research Pvt. Ltd. Website: https://actorius.in/ Contact page: https://actorius.in/contact

Explore career opportunities at Actorius Innovations. Join us to innovate with intent and make a difference in patient lives. Careers Join us to be a part of our Journey Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Culture For us, at Actorius, commitment to team work comes first. We have a flat hierarchy. We believe that it takes all sorts to make a formidable team. That’s why we are, at times, open to welcoming passionate and driven people to be a part of our growing team. Team Building We are open to welcoming passionate and driven people to be a part of our growing team. We hold off-sites and affiliation events to bring together members of the team. We take pride in investing in individualised talent development programme and mentoring. Our People Driven by People, Defined by Purpose. Whether you’re an experienced professional or a recent graduate, working with Actorius could be an enriching experience and rewarding next step in your career. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. 50+ and counting We’re looking for dynamic thinkers and doers to help us make a difference to patient lives. Apply Now Jobs Current Job Openings Current openings at Actorius Innovations and Research Didn't find any relevant openings? You think you are driven by a vision to positively changes the lives of cancer patients? or you have a passion for research, fill in the following form. if we have a position that we think you're suitable for, we'll reach out to you. Apply Proactively

Discover Actorius' journey. Learn how our innovation-driven, impact-obsessed start-up is revolutionizing early cancer detection. Our story so far An innovation-driven organisation 11000+ Patients Served 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Innovation Driven Impact-obsessed Who we are About Actorius We innovate and create bio materials that have critical applications in the field of life sciences, drug delivery and medical diagnostics. We work with a vision to advance and improve human health. Trusted by: Mission, Vision & Purpose Innovating with Intent Our mission, vision, and purpose reflect our commitment to meaningful progress and measurable outcomes. Mission To develop innovative methodologies to develop diagnostic tests that provide early indicators of oncogenesis and enable informed treatment strategies. Vision To collectively advance and improve human health by developing biomedical innovations into practical applications that have wider reach, accessibility and affordability. Purpose To positively impact everyone, by developing solutions that have reduced time to decision making and providing precise information for a chosen course of action. Our Values What We Stand For Our values define our commitment to rigorous science, responsibility, and meaningful impact. Work on challenges with cutting-edge science and innovation. Work towards making it accessible and affordable to the masses. Ensure critical clinical validations for every outcome. Bio-materials with high specificity, efficiency and sensitivity. Scientific disciplines with interdisciplinary intelligence at the core. Take every little step to ensure cancer patient’s lives are saved. Focused on creating novel cancer diagnostic tests. Know more Rigour in every action. Every product undergoes intense design and development. Leaving no stone unturned. We follow the most stringent quality norms like ISO13485 and regulatory requirements. Passionate and emphatic. We are committed to developing solutions for unmet medical needs. We build high-risk innovative products, which have a very long life-cycle, using novel biomaterials. Detect cancer relapse early, when it can be cured. We are committed to bringing stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care. India has a breakthrough in early cancer detection. Know More

Magnetically activated nanocellulose enables efficient CTC capture in head & neck cancer. Publications 20 September 2023 Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. In this report, the relative efficiency of cellulose nanocrystals (CNCs) and nanofibers (CNFs) to capture circulating tumor cells (CTCs) from the blood samples of head and neck cancer (HNC) patients was evaluated. Detection and enumeration of CTCs are critical for monitoring cancer progression. Both types of nanostructured cellulose were chemically modified with epithelial cell adhesion molecule (EpCAM) antibody and iron oxide nanoparticles. The EpCAM antibody facilitated the engagement of CTCs, promoting their entrapment within the cellulose cage structure. Iron oxide nanoparticles, on the other hand, rendered the cages magnetically activatable, enabling the capture and separation of entrapped CTCs using a magnet. The efficiency of the network structures was demonstrated using blood samples from head and neck cancer patients. It was observed that the degree of chemical functionalization of hydroxyl groups within the CNCs or CNFs with anti-EpCAM determined the efficiency of the system’s interaction with CTCs. Furthermore, the results indicated that the inflexible scaffolds of nanocrystals interacted more efficiently with CTCs than the fibrous CNF scaffolds. Network structures derived from CNCs demonstrated comparable CTC-capturing efficiency to the commercial standard, OncoDiscover®. The findings of this work provide chemical design principles for cellulosic materials intended to construct affordable platforms for monitoring cancer progression in real time. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Combined CTC and ctDNA analysis improves monitoring of metastatic colorectal cancer. Publications 17 October 2025 Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Background Combined analysis of biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) overexpressing tumorigenic proteins offers insight into evolving genotypic transitions from primary tumors that lead to metastasis in distant organs. We report the comparative distribution of CTCs and ctDNA genomic profiling in patients stratified as primary colorectal cancer (CRC) patients alone and those with metastasis progression in the liver, lung, and lymph nodes. Methods Retrospectively, we analyzed 218 patients with primary CRC (n = 153; male n = 93 and female n = 60). Metastasis was accounted for in 65 patients, namely liver (n = 27), lung (n = 8), and lymph nodes (n = 30). A total of 285 peripheral blood samples (218 baseline and 67 follow-up) were analyzed for the distribution of CTCs and ctDNA with driver mutations. CTCs expressing PD-L1 were evaluated using the CDSCO-approved OncoDiscover platform using 1.5 ml of blood. CTCs were enumerated based on EpCAM+, CK18+, DAPI+, and CD45– markers using a Zeiss automated fluorescence microscope. Further, the OncoIndx comprehensive NGS assay was performed using a 1080-gene panel. Results At baseline, 64.8% of primary CRC patients had ≥1 CTC (mean CTC distribution ~1.1), while 55.9% of patients had detectable ctDNA. In patients with metastasis (n = 65), the mean CTC distribution was 1.8. Higher CTC distribution was observed in liver metastasis (41.5%), lymph node involvement (46.2%), and lung metastasis (12.3%). A total of 71.7% of patients had detectable CTCs, among which 88.2% showed PD-L1 expression, while 61.3% of patients had detectable ctDNA. Concordance rates were 83.7% and 100% between the presence of CTCs and ctDNA in baseline and follow-up samples from patients with primary cancer, respectively. Furthermore, a strong correlation was observed between elevated CTC counts and the presence of ctDNA mutations in key oncogenes, including KRAS, EGFR, and BRAF. Conclusions Higher co-occurrence of ctDNA with CTCs at both baseline and follow-up highlights the need for monitoring disease progression and assessing treatment response. Thus, combined analysis of CTCs and ctDNA provides significant prognostic value in metastatic colorectal cancer. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius Innovations at ASCO Annual Meeting 2026 Publications 17 March 2026 ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Abstract Background Tumor thrombus (TT) refers to the direct extension of tumor cells into a blood vessel and is often detected incidentally. It is commonly observed in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and Wilms tumor. The presence of TT significantly worsens prognosis and alters disease staging. TT is frequently located in vessels such as the renal vein, inferior vena cava, and portal vein, requiring multidisciplinary evaluation due to its aggressive nature and risk of obstruction or embolization. Diagnostic differentiation between tumor thrombus and a “bland” thrombus (blood clot) typically relies on imaging techniques such as CT or MRI. In this study, we evaluated the association and potential role of circulating tumor cells (CTCs) expressing immune-relevant markers, such as PD-L1, in patients with tumor thrombus. The presence of CTCs originating from TT margins may help refine risk stratification and therapeutic decision-making. Methods In this observational study, 12 patients aged 51–80 years with confirmed tumor thrombus were analyzed. The cohort included patients with hepatocellular carcinoma (HCC, n = 4), pancreatic cancer (n = 3), liver cancer (n = 3), renal cell carcinoma (RCC, n = 1), and gallbladder cancer (GB, n = 1). Blood samples were analyzed for the presence of CTCs with PD-L1 expression at baseline, and three patients also had follow-up samples. Samples were processed using the CDSCO-approved OncoDiscover CTC enrichment technology. CTCs were identified using an automated Zeiss microscope based on EpCAM⁺, CK18⁺, DAPI⁺, CD45⁻, and PD-L1⁺ markers. Results A total of 16 CTCs were detected in 10 patients (83.33%) from 1.5 mL blood samples, with counts ranging from 1 to 6 CTCs per patient. At baseline, patients with HCC, pancreatic, RCC, gallbladder, and other cancers showed the presence of PD-L1–expressing CTCs. Follow-up samples revealed persistent CTC positivity, although the number of PD-L1–positive CTCs decreased. The mean CTC distribution was 1.33 for CK18-expressing CTCs. PD-L1–positive CTCs were detected in a substantial subset, with a mean distribution of 0.67 (9 CTCs among 12 patients), indicating immune-evasive potential. CTC clusters were rare and detected in only one HCC patient but persisted during follow-up. Both male and female patients demonstrated comparable CTC positivity. Conclusion The presence of CTCs in peripheral blood highlights active tumor cell dissemination from tumor thrombus margins. Although CTC clusters were infrequent, their occurrence may indicate an increased metastatic risk. This study demonstrates, for the first time, the presence of CTCs originating from tumor thrombus margins entering systemic circulation. Further studies are required to better understand their clinical implications. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Preoperative CTC levels predict prognosis and survival in oral squamous cell carcinoma. Publications 1 July 2022 Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Objective: The aim of this study was to investigate the presence of circulating tumor cells (CTCs) and their correlation with prognostic factors and clinical outcomes in treatment-naive patients with oral squamous cell carcinoma. Study design: CTCs were isolated using the OncoDiscover technique from presurgically obtained peripheral blood of 152 patients with treatment-naive oral squamous cell carcinoma. Sensitivity analysis was performed by including 40 healthy controls. CTC cutoff values for clinicopathologic factors were obtained from receiver operating characteristic curves. Multivariate models determined the significance of CTCs as independent variables. Kaplan–Meier analysis differentiated overall survival based on CTC values corresponding to disease stage. Results: Sensitivity, specificity, and accuracy of CTC detection were 94.32%, 98%, and 95.17%, respectively. The platform differentiated true positives at >3.5 CTCs (P < .00001). CTC counts above 20.5 were suggestive of nodal metastasis (P < .0001), with a linear trend for detecting occult metastasis (P = .061). Early and advanced stages could be differentiated by >13.5 CTCs (P < .0001). Elevated CTC levels were significantly associated with extranodal extension (>21.45 CTCs, P = .025), perineural invasion (>19.35 CTCs, P = .049), and depth of invasion (>12.5 CTCs, P = .0038). Median survival was reduced by 19 months when CTC levels were >13. Conclusions: Preoperative CTC levels demonstrated a strong correlation with adverse clinicopathologic factors and suggested their role as a sensitive prognostic marker for predicting survival outcomes and disease progression. (Oral Surg Oral Med Oral Pathol Oral Radiol 2022;134:73–83) View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Automated OncoMetastat device enables CTC removal to support cancer therapy outcomes. Publications 3 November 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Introduction Despite no radiological evidence of minimal residual disease, up to 25–50% of colorectal cancer (CRC) stage II–III and breast cancer cases experience relapse. Identifying patients at risk of recurrence remains challenging, as approximately 90% of cancer-related deaths are associated with metastasis. The role of circulating tumor cells (CTCs) in extravasation and seeding of distant organs is well established; however, their extracorporeal isolation has not been widely demonstrated in routine practice. Current ex vivo CTC isolation systems often require complex setups and extensive manual handling. In this study, we present an automated device designed to capture and remove CTCs from whole blood using biocompatible cartridges mediated by antibody- and transferrin-conjugated glass bead substrates. Methods We developed the OncoMetastat touchscreen-based operational control device, integrating six roller peristaltic pumps and a cartridge containing 680 targeting 2 mm glass beads functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies and transferrin protein. The device housing (365 × 200 × 30 mm) contains a bi-spiral channel (95 × 95 × 10 mm) with 680 beads and eight cross-section channels (3.50 × 3.55 mm). A 3D-printed spring-loaded quick-release mechanism ensures secure tube attachment and rapid cartridge exchange. Flow performance, hemolysis, protein adsorption, and leukocyte interaction were evaluated using blood samples from healthy individuals and cancer patients across multiple cancer types, including breast, CRC, lung, and head and neck cancers. Pyrogenicity was assessed in rabbits according to ISO 10993-11 guidelines. Results The device maintained stable blood circulation at 0.5 mL/min for 5–10 mL whole blood samples using a dual snap-fit holder with a 2° angled offset. The peristaltic pump ensured consistent flow without compromising sample integrity. The bead-filled spiral channel effectively retained CTCs, while the integrated design reduced manual handling and improved reproducibility. Low hemolysis (1%), along with reduced serum protein and leukocyte interactions, was observed in both healthy and cancer patient samples. Selective CTC capture was demonstrated in 24 clinical samples across cancer types. All materials passed pyrogenicity testing, with no temperature elevation observed in accordance with guidelines. Conclusions The OncoMetastat device successfully depleted CTCs from cancer patient whole blood without adversely affecting blood components. The automated system provides stable blood flow and demonstrates proof of performance for extracorporeal CTC removal, with potential to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 analysis helps detect MRD and guide therapy in colorectal cancer. Publications 3 June 2024 ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Background In stage III colorectal cancer (CRC) patients, the extent of oxaliplatin-based adjuvant therapy remains uncertain. Approximately 25–50% of stage II–III CRC patients develop recurrence and metastasis even after comprehensive treatment, largely attributed to occult disease and minimal residual disease (MRD). Circulating tumor cells (CTCs) represent a bio-mechanistic source of extravasation leading to micro-metastatic disease. CRC patients receiving reduced adjuvant therapy (3–6 months) are known to exhibit increased CTC counts and positivity rates due to the emergence of resistant clones. Assays that detect CTCs and the expression of programmed death-ligand 1 (PD-L1) as a dynamic biomarker simultaneously have significant clinical implications, particularly when tissue biopsy samples are inadequate to identify molecular targets for immune checkpoint inhibitor (ICI) therapy. Methods In a retrospective study, 182 CRC patients were analyzed for the presence and distribution of CTCs at baseline and across follow-ups (0–4 follow-ups). Peripheral blood (1.5 ml) samples were analyzed using the CDSCO-approved OncoDiscover platform, which consists of a multifunctional magneto-nanosystem mediated by anti-epithelial cellular adhesion molecule (EpCAM) antibodies. CTCs were evaluated in patients with early-stage disease (pre- and post-treatment), progressive disease, disease-free status (DFS), and metastasis. Isolated cells were immunostained to detect CK18+, CD45-, DAPI+, and PD-L1+ expression. PD-L1 expression on CTCs was validated by analyzing the linear intensity gradients of fluorescence signals. CTCs were classified as PD-L1 negative when weak or no fluorescence signal was detected and PD-L1 positive when strong fluorescence signals were observed using automated image acquisition on a Zeiss fluorescence microscope. Results Among the cohort of 182 CRC patient samples, 128 (70.3%) showed the presence of CTCs. A fluorescence intensity-based assay was developed to evaluate PD-L1 expression as a robust functional biomarker for molecular characterization of CTCs. The distribution of CTCs ranged from 1 to 9 cells. The mean fluorescence intensity value and cut-off for PD-L1 expression in CTCs was approximately 1.02. Notably, 54 patients (42.2%) with CTCs showed positive PD-L1 expression. CTC-positive patients with PD-L1 expression were observed across all stages, including early-stage disease, progressive disease, and metastasis. Patients without detectable CTCs (n = 54, 29.7%) either had clinically stable disease or were in DFS with no radiographic evidence of disease. Conclusions PD-L1 overexpression on CTCs represents a dynamic blood-based biomarker indicating disease progression even in patients with DFS status. Enumeration of CTCs along with assessment of PD-L1 expression may enable more individualized treatment strategies for CRC patients and support better monitoring of disease progression and therapeutic response. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Dual ctDNA and CTC biomarkers improve detection of cancer progression. Publications 3 June 2024 ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Background Genomic mutations identified from circulating tumor DNA (ctDNA) have been shown to correlate positively with clinical disease status. EGFR and intracellular cell progression and proliferation pathways involving BRCA1/2 and TP53 genes drive high ctDNA load in progressive cancer patients. Circulating tumor cells (CTCs) indicate cellular residual disease (CRD). Together, ctDNA and CTCs as dual biomarkers offer predictive insights into tumor progression and metastasis, which may be valuable for early detection and treatment modifications. Methods In a retrospective study, 96 cancer patients (including lung, colorectal, breast, stomach, and other cancers) who had recently undergone treatment were investigated for the presence of CTCs and genomic mutations from ctDNA using the OncoMonitor test. Libraries were prepared using a hybridization-capture method covering 1000 targets with a mean sequencing depth of 5000× on the Illumina NextSeq 2000 platform. The test detected genomic alterations including single nucleotide variations (SNVs), small insertions and deletions (INDELs), copy number variations (CNVs), and translocations (fusions) using a 96-gene panel. CTCs were isolated using the OncoDiscover platform and identified as CK18+, PD-L1+, CD45- cells in 1.5 ml of blood. Results Among the 96 pan-cancer patients, 15.6% (n = 15) were identified with localized progressive disease without metastasis based on radiological findings, of which 60% (n = 9) showed at least one genomic alteration detected from ctDNA. Additionally, 12.5% (n = 12) patients were identified with metastatic disease from radiological findings, of which 58.3% (n = 7) showed the presence of at least one CTC. Among these, 33.3% (n = 4) patients had two CTCs, while five patients had no detectable CTCs. Furthermore, metastatic patients showed ctDNA load in 66.6% (n = 8) of cases with at least one genomic finding. In the metastatic disease cohort, CTC enumeration showed a concordance of 58.3% (n = 7) with metastatic radiological findings, while genomic findings from ctDNA showed a concordance of 66.6% (n = 8) with metastatic radiological findings. Among 23.9% (n = 23) patients identified radiologically with stable or treatment-responsive disease, 73.9% (n = 17) had no detectable genomic mutations from ctDNA, and 26.0% (n = 6) were CTC-negative, consistent with radiological findings. However, 26.0% (n = 6) patients had at least one genomic finding, contributing to discordance with radiological findings. Overall, genomic findings from the dual biomarkers showed concordance with radiological findings in 26.6% (n = 4) patients with progressive disease, 41.6% (n = 5) patients with metastatic disease, and 17.3% (n = 4) patients with stable or treatment-responsive disease. Conclusions Patients with progressive and metastatic disease identified through radiological findings showed concordance with dual ctDNA and CTC biomarkers. The concordance of ctDNA in progressive disease and CTC detection in metastatic disease highlights the individual significance of these biomarkers and supports their combined use for monitoring disease status and guiding treatment decisions. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe